Cardiovascular Risk Reduction in Patients With Chronic Kidney Disease: Potential for Targeting Inflammation With Canakinumab
Overview
Affiliations
Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.
Frak W, Dabek B, Balcerczyk-Lis M, Motor J, Radzioch E, Mlynarska E Antioxidants (Basel). 2024; 13(6).
PMID: 38929126 PMC: 11200916. DOI: 10.3390/antiox13060687.
Xu J, Xue Z, Zhang Y, Liu X, Zhang X, Yang X J Geriatr Cardiol. 2024; 21(4):443-457.
PMID: 38800544 PMC: 11112150. DOI: 10.26599/1671-5411.2024.04.007.
Novel Therapeutic Approaches in the Management of Chronic Kidney Disease.
Dabek B, Dybiec J, Frak W, Fularski P, Lisinska W, Radzioch E Biomedicines. 2023; 11(10).
PMID: 37893119 PMC: 10604464. DOI: 10.3390/biomedicines11102746.
Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance.
Liu Y, Lei H, Zhang W, Xing Q, Liu R, Wu S Cell Death Dis. 2023; 14(7):472.
PMID: 37500614 PMC: 10374588. DOI: 10.1038/s41419-023-06005-6.
Chronic Kidney Disease as a Comorbidity in Heart Failure.
Szlagor M, Dybiec J, Mlynarska E, Rysz J, Franczyk B Int J Mol Sci. 2023; 24(3).
PMID: 36769308 PMC: 9918100. DOI: 10.3390/ijms24032988.